Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: Patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones

Neuropharmacology

Volumn 37, Issue 6, 1998, Pages 719-727

  Parsons, Chris G ^a   Hartmann, Sabine ^a   Spielmanns, Peter ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Amantadine; Budipine; Cortical and hippocampal cultures; Memantine; Patch clamp; Striatal; Uncompetitive N methyl D aspartate receptor antagonist

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BUDIPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ARTICLE; BINDING KINETICS; BRAIN CORTEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENCY; EMBRYO; HIPPOCAMPUS; NERVE CELL CULTURE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SUPERIOR COLLICULUS;

AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO; HIPPOCAMPUS; MEMANTINE; NEOSTRIATUM; NEURONS; PATCH-CLAMP TECHNIQUES; PIPERIDINES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SUPERIOR COLLICULUS;

EID: 0031811332     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00059-8     Document Type: Article

References (41)

1. Blanpied T.A., Boeckman F.A., Aizenman E., Johnson J.W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77:1997;309-323.
2. Bresink I., Benke T.A., Collett V.J., Seal A.J., Parsons C.G., Henley J.M., Collingridge G.L. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br. J. Pharmacol. 119:1996;195-204.
3. Carlsson M., Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
4. Chen H.S.V., Lipton S.A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. Lond. 499:1997;27-46.
5. Chen H.S.V., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine - therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4436.
6. Danysz W., Gossel M., Zajaczkowski W., Dill D., Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural Transm. [P-D Sect.]. 7:1994;155-166.
7. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drug News Perspect. 8:1995;261-277.
8. Danysz W., Parsons C.G., Kornhuber J., Schmidt W., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
9. Fletcher E.J., Church J., Abdel Hamid K., Macdonald J.F. Blockade by sigma site ligands of N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurones. Br. J. Pharmacol. 116:1995;2791-2800.
10. Frankiewicz T., Potier B., Bashir Z.I., Collingridge G.L., Parsons C.G. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. 117:1996;689-697.
11. Honegger U.E., Quack G., Wiesmann U.N. Evidence for lysosomotropism of memantine in cultured human cells - cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Pharmacol. Toxicol. 73:1993;202-208.
12. Jackisch R., Huang H.Y., Reimann W., Limberger N. Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J. Pharmacol. Exp. Ther. 264:1993;889-898.
13. Jackisch R., Kruchen A., Sauermann W., Hertting G., Feuerstein T.J. The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur. J. Pharmacol. 264:1994;207-211.
14. Jellinger K., Bliesath H. Adjuvant treatment of Parkinsons disease with budipine: a double-blind trial versus placebo. J. Neurol. 234:1987;280-282.
15. Klockgether T., Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism - agonist-sensitive sites in the basal ganglia. Ann. Neurol. 34:1993;585-593.
16. Klockgether T., Jacobsen P., Loschmann P.A., Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J. Neural Transm. [P-D Sect.]. 5:1993;101-106.
17. Klockgether T., Wullner U., Steinbach J.P., Petersen V., Turski L., Loschmann P.A. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur. J. Pharmacol. 301:1996;67-73.
18. Kornhuber J., Bormann J., Hubers M., Rusche K., Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. Eur. J. Pharmacol. Mol. Pharmacol. 206:1991;297-300.
19. Kornhuber J., Schoppmeyer K., Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci. Lett. 163:1993;129-131.
20. Kornhuber J., Herr B., Thome J., Riederer P. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J. Neural Transm. Suppl. 46:1995;131-137.
21. Kornhuber J., Parsons C.G., Hartmann S., Retz W., Kamolz S., Thome J., Riederer P. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural Transm. Gen. Sect. 102:1995;237-246.
22. Lupp A., Lucking C.H., Koch R., Jackisch R., Feuerstein T.J. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J. Pharmacol. Exp. Ther. 263:1992;717-724.
23. Menge, H.G., Brand, U., 1985. Pharmacologic basis of antiparkinsonian therapy. In: Gerstenbrand, F., Poewe, W., Stern, G. (Eds.), Clinical Experiences with Budipine in Parkinson Therapy. Springer Verlag, Berlin, pp. 82-92.
24. Monnet F.P., Debonnel G., Demontigny C. In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J. Pharmacol. Exp. Ther. 261:1992;123-130.
25. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors - molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
26. Parsons C.G., Gruner R., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 32:1993;1337-1350.
27. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 34:1995;1239-1258.
28. Parsons C.G., Panchenko V.A., Pinchenko V.O., Tsyndrenko A.Y., Krishtal O.A. Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci. 8:1996;446-454.
29. Parsons, C.G., Danysz, W., Bartmann, A., Spielmanns, P., Frankiewicz, T., Hesselink, M., Eilbacher, B., Quack, G.,. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology, in press.
30. Porter R.H.P., Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64:1995;614-623.
31. Priestley T., Ochu E., Macaulay A.J. Time-dependent changes in NMDA receptor expression in neurones cultured from rat brain. Mol. Brain Res. 40:1996;271-274.
32. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists - channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
33. Schmidt W.J., Bubser M., Hauber W. Behavioural pharmacology of glutamate in the basal ganglia. J. Neural Transm. [P-D Sect.]. 38:1992;65-89.
34. Stoof J.C., Booij J., Drukarch B., Wolters E.C. The anti-Parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharmacol. 213:1992;439-443.
35. Subramaniam S., Donevan S.D., Rogawski M.A. Hydrophobic interactions of n-alkyl diamines with the N-methyl-D-aspartate receptor - voltage-dependent and -independent blocking sites. Mol. Pharmacol. 45:1994;117-124.
36. Ujihara H., Albuquerque E.X. Ontogeny of N-methyl-D-aspartate-induced current in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 263:1992;859-867.
37. Wang L.Y., Macdonald J.F. Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J. Physiol. Lond. 486:1995;83-95.
38. Wang L.Y., Orser B.A., Jia Z., Roder J., Macdonald J.F. Magnesium and ketamine increase the affinity of NMDA receptors for glycine. Soc. Neurosci. Abstr. 20:1994;734.
39. Weller M., Finielsmarlier F., Paul S.M. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res. 613:1993;143-148.
40. Williams K., Russell S.L., Shen Y.M., Molinoff P.B. Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron. 10:1993;267-278.
41. Zech, K., Sturm, E., Ludwig, G., 1985. Pharmacokinetics and metabolism of budipine in animals and humans. In: Gerstenbrand, F., Poewe, W., Stern, G. (Eds.), Clinical Experiences with Budipine in Parkinson Therapy. Springer Verlag, Berlin, pp. 113-121.